Form 6-K BioLineRx Ltd. For: Feb 04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- AMD shares fall amid AI chip sector selloff
- Alphabet shares drop ahead of earnings next week
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
BioLineRx (BLRX) Plans Offering of ADSs and Warrants
February 4, 2019 4:43 PM ESTBioLineRx (NASDAQ: BLRX) a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has commenced an underwritten public offering of American Depositary Shares (ADSs), each representing one of its ordinary shares with each ADS to be sold together in a fixed combination with a warrant to purchase ADSs. All of the securities in the offering are to be... More



